0Y6X Stock Chart & Stats
$91.12
$1.72(1.98%)
At close: 4:00 PM EDT
$91.12
$1.72(1.98%)
Day’s Range― - ―
52-Week Range$73.00 - $106.66
Previous CloseN/A
Volume8.29K
Average Volume (3M)6.82K
Market Cap
$120.46B
Enterprise Value$129.69K
Total Cash (Recent Filing)$1.79B
Total Debt (Recent Filing)$28.15B
Price to Earnings (P/E)23.0
Beta0.50
Next Earnings
Nov 24, 2026EPS Estimate
1.33Next Dividend Ex-DateN/A
Dividend Yield3.02%
Share Statistics
EPS (TTM)4.09
Shares Outstanding1,279,138,000
10 Day Avg. Volume10,363
30 Day Avg. Volume6,818
Financial Highlights & Ratios
PEG Ratio6.72
Price to Book (P/B)2.16
Price to Sales (P/S)2.94
P/FCF Ratio19.68
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$103.41Price Target Upside13.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)5.97
Revenue Forecast (FY)$39.01B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation And Improving ProfitabilityMedtronic’s substantial operating and free cash flow provides resilience and funding for research, commercial investment, acquisitions, and shareholder returns. Combined with high gross margins and improving operating profitability, this supports durable financial flexibility over the next several quarters.
Innovation Platforms Gaining AdoptionRapid adoption across cardiac ablation and robotic surgery platforms indicates that newer products are expanding Medtronic’s growth opportunities beyond mature device categories. Increasing procedure volumes and share gains can strengthen the portfolio’s long-term revenue mix.
Strategic Expansion In Structural HeartThe Pi-Cardia investment and planned distribution rights give Medtronic an additional pathway to address increasingly complex TAVR procedures. This strengthens its structural-heart pipeline and may broaden future offerings where current portfolio momentum is weaker.
Bears Say
Elevated Absolute Debt Reduces FlexibilityAlthough equity supports a moderate leverage profile, the sizeable debt balance can reduce financial flexibility if growth slows or capital costs rise. Higher leverage may constrain the pace of acquisitions, investment, or other capital-allocation decisions over the medium term.
Tariffs Are An Ongoing Margin HeadwindTariff costs directly pressure gross margin and are already embedded in forward guidance, making them a continuing drag rather than a one-quarter issue. Further trade actions could increase the burden and limit the benefit of operational efficiency.
Structural Heart And Diabetes Mix PressureWeakness in Structural Heart, including TAVR, limits growth in an important therapy area, while Diabetes and capital-goods mix pressure margins. These issues can weigh on consolidated growth quality and profitability until portfolio performance improves.
Medtronic News
0Y6X FAQ
What was Medtronic’s price range in the past 12 months?
Medtronic lowest share price was $73.00 and its highest was $106.66 in the past 12 months.
What is Medtronic’s market cap?
Medtronic’s market cap is $120.46B.
When is Medtronic’s upcoming earnings report date?
Medtronic’s upcoming earnings report date is Nov 24, 2026 which is in 77 days.
How were Medtronic’s earnings last quarter?
Medtronic released its earnings results on Sep 01, 2026. The company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.388 by $0.062.
Is Medtronic overvalued?
According to Wall Street analysts Medtronic’s price is currently Undervalued.
Does Medtronic pay dividends?
Medtronic pays a Quarterly dividend of $0.72 which represents an annual dividend yield of 3.02%. See more information on Medtronic dividends here
What is Medtronic’s EPS estimate?
Medtronic’s EPS estimate is 1.33.
How many shares outstanding does Medtronic have?
Medtronic has 1,279,138,000 shares outstanding.
What happened to Medtronic’s price movement after its last earnings report?
Medtronic reported an EPS of $1.45 in its last earnings report, beating expectations of $1.388. Following the earnings report the stock price went up 1.651%.
Which hedge fund is a major shareholder of Medtronic?
Currently, no hedge funds are holding shares in GB:0Y6X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medtronic Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$103.41 (13.49% Upside)
$103.41 (13.49% Upside)
Blogger Sentiment
Bullish
GB:0Y6X Sentiment 78%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth $337.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.71%
12-Months-Change
Fundamentals
Return on Equity
3.02%
Trailing 12-Months
Asset Growth
2.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Medtronic
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
0Y6X Company Deck
0Y6X Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial picture: strong quarterly and annual revenue growth, EPS outperformance, robust free cash flow, multiple high-growth product area accelerations (CAS, Symplicity, Hugo, Altaviva), and deliberate M&A/venture activity to drive future growth. Notable headwinds include tariffs and trade uncertainty, some product‑mix and Diabetes-related margin pressure, pockets of weakness in Structural Heart (TAVR) and select therapy areas, and near-term investment-driven SG&A/R&D increases. Management provided confident FY '27 guidance while conservatively modeling separation and tariff risks.View all GB:0Y6X earnings summaries0Y6X Net sales Breakdown
36.56% Cardiovascular
29.06% Neuroscience
26.01% Medical Surgical
7.69% Diabetes
0.68% Other operating segment
0Y6X Stock 12 Month Forecast
Average Price Target
$103.41
▲(13.49% Upside)